US 2025/0017893 A1 · FISETIN NANOPARTICLES

Abstract

The present invention relates to a plurality of fisetin nanoparticles in poly(lactic-co-glycolic) acid (PLGA). The nanoparticles, characterized by a specific size, showed excellent stability and pharmacokinetics, therefore optimal properties for their use in pharmaceutical compositions or in the preparation of supplements and food supplements, to be used in particular for the prevention and treatment of bone diseases and for the treatment of cleidocranial dysplasia.

Claims30

Dependent claims

A plurality of fisetin nanoparticles in poly(lactic-co-glycolic) acid (PLGA), wherein each particle has a diameter in the range from 120 to 160 nm.

Dependencies are inferred from the claim text.

Facts

Application

18/713,198Filed 25 Nov 2022

Priority

IT 10202100002998726 Nov 2021

Published

16 Jan 2025

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/352
Having six-membered rings with one oxygen as the only ring hetero atom: condensed with carbocyclic rings, e.g. methantheline
A23K 20/105
Organic substances: aliphatic or alicyclic compounds
A23L 33/10
Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof: using additives

Abstract

Claims30

Dependent claims

A plurality of fisetin nanoparticles in poly(lactic-co-glycolic) acid (PLGA), wherein each particle has a diameter in the range from 120 to 160 nm.

Dependencies are inferred from the claim text.

Fisetin nanoparticles

Life of this patent

Abstract

Claims30

Fisetin nanoparticles

Life of this patent

Abstract

Claims30